Ethanol selectively enhances the hyperpolarizing component of neocortical neuronal responses to locally applied GABA.
Local application of GABA to rat cerebral cortical neurons in brain slices elicited biphasic responses mediated via GABAA receptors. The fast component of the response, which was most apparent with somatic application of GABA, was hyperpolarizing at the normal resting membrane potential (GABAh response). The slower component could be elicited by GABA application to nearly all regions of the cell, and was depolarizing at the resting membrane potential (GABAd response). The reversal potential of evoked IPSCs recorded with whole-cell patch electrodes (-68 mV) was comparable to the reversal potential of the GABAh response (-69 mV), and was significantly different from the reversal potential of the GABAd response (-56 mV). The GABAd response was more sensitive to enhancement by pentobarbital and more readily antagonized by both bicuculline and picrotoxin than the GABAh response. Recording in bicarbonate-free buffer changed the reversal potential of the GABAd response significantly, but had no effect on the GABAh response. In contrast, superfusion with ethanol significantly enhanced the GABAh response, while having no effect on the GABAd component. Although a localized collapse of the Cl- gradient, which has been proposed to underlie the GABAd response, could explain the greater sensitivity of the GABAd response to pentobarbital and the GABAA antagonists, this could not account for the greater sensitivity of the GABAh response to ethanol. Differences in GABAA receptor subunit composition may result in the expression of dendritic and somatic GABAA receptors that have different kinetics, reversal potentials, and sensitivity to pharmacological agents, including ethanol.
Soldo
B L
BL
Department of Pharmacology and Program in Neuroscience, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
Proctor
W R
WR
Dunwiddie
T V
TV
D000818:Animals; D002492:Central Nervous System Depressants / Q000494:pharmacology*; D004594:Electrophysiology; D000431:Ethanol / Q000494:pharmacology*; D005445:Flunitrazepam / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D018757:GABA Modulators / Q000494:pharmacology; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D019579:Neocortex / Q000166:cytology*; D009474:Neurons / Q000737:chemistry / Q000187:drug effects*; D010424:Pentobarbital / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000502:physiology; D013569:Synapses / Q000737:chemistry / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology*
D002492:Central Nervous System Depressants; D000431:Ethanol; D005445:Flunitrazepam; D018756:GABA Antagonists; D018757:GABA Modulators; D010424:Pentobarbital; D010852:Picrotoxin; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid